Never double up on doses to make up for a missed injection
F.LevineS
There is strong evidence from randomised cardiovascular outcome trials (CVOTs) that several long-acting GLP-1 RAs (liraglutide, dulaglutide and subcutaneous semaglutide) provide cardiovascular protection to individuals with T2D with pre-existing cardiovascular disease (secondary prevention) or at high risk of CV events, and to a lesser extent those without overt atherosclerotic vascular disease (primary prevention
Hence, in addition to enhanced blood glucose control, the researchers explained in their paper, GLP-1 receptor agonist therapy may confer additional benefits
Our goal here is practical clarity: to unpack how these tools work, what risks matter most, when they help women, and how to navigate safety, dosing, and the bigger lifestyle context that makes any of this effective
Your package of one injectable pen will include 4 needles